Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.33 |
| ▸ | BUB1 | O43683 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
| ▸ | CCNK | O75909 | 1/20 | 0.31 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5454741 | 1.00 | CA2 (0.38) | CA2HCRTR1HCRTR2BUB1MAPK14 | |
| SCHEMBL5454799 | 1.00 | CA2 (0.38) | CA2HCRTR1HCRTR2BUB1MAPK14 | |
| SCHEMBL3867867 | 0.83 | PTGES (0.36) | CA2HCRTR1HCRTR2BUB1 | |
| SCHEMBL3861428 | 0.83 | PTGES (0.36) | CA2HCRTR1HCRTR2BUB1 | |
| SCHEMBL3861427 | 0.83 | PTGES (0.36) | CA2HCRTR1HCRTR2BUB1 | |
| SCHEMBL1486694 | 0.81 | MAPK14 (0.38) | BUB1MAPK14 | |
| SCHEMBL34467720 | 0.78 | TNF (0.33) | — | |
| SCHEMBL3869962 | 0.75 | KCNH2 (0.42) | — | |
| SCHEMBL3861791 | 0.74 | IDO1 (0.41) | — | |
| SCHEMBL21949825 | 0.74 | EGFR (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070259881-A1 | Substituted Imidazo Ring Systems and Methods | COLEY PHARMACEUTICAL GROUP, INC. | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259881-A1 | Substituted Imidazo Ring Systems and Methods | IL2, IL4, IRF3 | CA2 3918/4885HCRTR1 3273/4885HCRTR2 2926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.